Table 1

Baseline characteristics according to susceptibility vessel sign (SVS) on MRI

CharacteristicsSVS–
(n=52)
SVS+
(n=165)
P values†
Demographics
Age, years, mean (SD)65.7 (14.1)64.5 (15.4)0.98
Men21/52 (40.4)91/165 (55.2)0.095
Medical history
Hypertension33/52 (63.5)79/161 (49.1)0.17
Diabetes13/52 (26.5)17/163 (10.4)0.066
Hypercholesterolemia19/49 (38.8)60/155 (38.7)0.89
Current smoking8/45 (17.8)33/143 (23.1)0.49
Coronary artery disease9/51 (17.6)21/161 (13.0)0.78
Current stroke event
Systolic blood pressure, mmHg, mean (SD)‡142.1 (26.1)142.1 (22.9)0.85
Diastolic blood pressure, mmHg, mean (SD)‡81.0 (17.4)81.0 (15.1)0.86
Glycemia, median (IQR)§6.6 (5.6 to 7.7)6.7 (5.9 to 8.2)0.071
NIHSS score, mean (SD)¶16.2 (6.0)16.7 (5.6)0.91
ASPECTS, median (IQR)**7 (5 to 8)7 (5 to 8)0.66
Site of occlusion0.082
 M1/M240/52 (76.9)144/165 (87.3)
 ICA12/52 (23.1)21/165 (12.7)
Intravenous rt-PA35/52 (67.3)141/165 (85.5)0.15
Etiology0.38
 Atherothrombotic8/51 (15.7)17/161 (10.6)
 Cardioembolic17/51 (33.3)72/161 (44.7)
 Other or unknown causes26/51 (51.0)72/161 (44.7)
Favorable collaterality10/42 (23.8)26/139 (18.7)0.56
Intervals times, min, median (IQR)
Onset to groin puncture time††220 (165 to 296)215 (180 to 255)0.57
Onset to imaging‡102 (72 to 135)115 (88.5 to 141)0.089
Onset to clot‡‡252 (200 to 325)248 (210 to 285)0.57
  • Values expressed as the no/total no (%) unless otherwise indicated.

  • P values were computed using logistic regression model adjusted for study (except for Intravenous rt-PA). 

  • †P values calculated after log- transformation of data.

  • ‡Two missing values (one in SVS+).

  • §Seven missing values (four in SVS+).

  • ¶One missing value in SVS–.

  • **Four missing values (three in SVS+).

  • ††Three missing values (two in SVS+).

  • ‡‡Five missing values (four in SVS+).

  • ASPECTS, Alberta Stroke Programme Early CT Score; ICA, internal carotid artery; IQR, IQR range; M1,M2, first or second segment of the middle cerebral artery; NIHSS, National Institutes of Health Stroke Scale; rt-PA, recombinant tissue plasminogen activator; SVS, susceptibility vessel sign.